Indeed, the large phase 3 diabetic neuropathy NGF clinical trial failed because the threshold of the administered hNGF WT, that provoked pain in patients, coincided with the minimal pharmacologically effective dose (1 μg/kg) [18]. Here, NGF is linked to diabetic neuropathy.